| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
(-)-Huperzine A (Hup A; Selagine; (-)-Selagine) is a naturally occurring, highly specific and reversible inhibitor of acetylcholinesterase (AChE) with neuroprotective activity. It inhibits AChE with Ki of 7 nM, and exhibits 200-fold more selectivity for G4 AChE over G1 AChE. Chemically, (-)-Huperzine A is an active Lycopodium alkaloid isolated from traditional Chinese herb. It also acts as an NMDA receptor antagonist. (-)-Huperzine A has been investigated as a possible treatment for diseases characterized by neurodegeneration-particularly Alzheimer's disease. Huperzine A is also marketed as a dietary supplement with claims made for its ability to improve memory and mental function.
| ln Vitro |
(-)-Huperzine A (1 μM; 2 hours) attenuates neuronal damage caused by Aβ23-35 (20 μM) [2]. (-)-Huperzine A (100 μM) reversibly suppresses NMDA-induced currents (IC50=126 μM) in whole-cell voltage-clamp recordings in CA1 pyramidal neurons that had been acutely separated from the rat hippocampal [3].
|
|---|---|
| ln Vivo |
In rats with degeneration brought on by icv infusion of beta-amyloid-(1-40), (-)-Huperzine A (0.1-0.2 mg/kg; intraperitoneal injection; daily; for 12 days) lessens neuronal damage and cognitive dysfunction [5].
|
| Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) rats (220-280 g)[5]
Doses: 0.1 mg/kg, 0.2 mg/kg Route of Administration: intraperitoneal (ip)injection, daily, for 12 days Experimental Results: Partly reversed the down-regulation of anti-apoptotic Bcl-2 and the up-regulation of pro-apoptotic Bax and P53 proteins and decreased the apoptosis that normally followed b-amyloid injection; alleviated the cognitive dysfunction induced by b-amyloid protein-(1-40). |
| References |
[1]. MA Xiao-Chao, XIN Jian, WANG Hai-Xue, et al. Acute effects of huperzine A and tacrine on rat liver. Acta Pharmacol ogica Sinica, 2003, 24(3):247-250.
[2]. Rui Wang, et al. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 Jan;27(1):1-26. [3]. J M Zhang, et al. Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.Neuroscience. 2001;105(3):663-9 [4]. Maung Kyaw Moe Tun, et al. The pharmacology and therapeutic potential of (−)-huperzine A. J Exp Pharmacol. 2012; 4: 113–123. [5]. R Wang, et al. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur J Pharmacol. 2001 Jun 15;421(3):149-56. |
| Molecular Formula |
C15H18N2O
|
|
|---|---|---|
| Molecular Weight |
242.32
|
|
| CAS # |
102518-79-6
|
|
| Related CAS # |
|
|
| SMILES |
O=C1C([H])=C([H])C2=C(C([H])([H])[C@]3([H])C([H])=C(C([H])([H])[H])C([H])([H])[C@]2(C3=C([H])C([H])([H])[H])N([H])[H])N1[H]
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1268 mL | 20.6339 mL | 41.2677 mL | |
| 5 mM | 0.8254 mL | 4.1268 mL | 8.2535 mL | |
| 10 mM | 0.4127 mL | 2.0634 mL | 4.1268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
